TY - JOUR
T1 - Continued investigation into the influence of loaded dose on the performance of dry powder inhalers
T2 - Surface smoothing effects
AU - El-Sabawi, Dina
AU - Edge, Stephen
AU - Price, Robert
AU - Young, Paul M.
PY - 2006
Y1 - 2006
N2 - The aerosolization of salbutamol sulfate, measured as fine particle dose (FPDLD) and fine particle fraction (FPFLD) (<6.4 μm mass median aerodynamic diameter), from two sieved (63–90 μm) lactose monohydrate carriers, one as supplied, one smoothed by controlled surface dissolution, was studied. In general, no significant variation in FPDLD was observed at drug loadings between 10 and 63.5 μg and 10 and 135 μg for the surface dissolved and as supplied lactose monohydrates, respectively. Increasing the drug load above these levels resulted in linear increases in FPDLD with increasing drug load with the surface dissolved lactose monohydrate exhibiting higher FPDLD and FPFLD. This suggests that, at lower drug loadings, areas of the carrier exhibiting higher adhesion, so-called active sites, were being preferentially occupied and filled. Since there was no evidence of drug agglomeration using scanning electron microscopy, the observations suggest that the number and range of such higher energy “active sites” can be reduced by modifying the surface roughness, that is, energies, of the carrier.
AB - The aerosolization of salbutamol sulfate, measured as fine particle dose (FPDLD) and fine particle fraction (FPFLD) (<6.4 μm mass median aerodynamic diameter), from two sieved (63–90 μm) lactose monohydrate carriers, one as supplied, one smoothed by controlled surface dissolution, was studied. In general, no significant variation in FPDLD was observed at drug loadings between 10 and 63.5 μg and 10 and 135 μg for the surface dissolved and as supplied lactose monohydrates, respectively. Increasing the drug load above these levels resulted in linear increases in FPDLD with increasing drug load with the surface dissolved lactose monohydrate exhibiting higher FPDLD and FPFLD. This suggests that, at lower drug loadings, areas of the carrier exhibiting higher adhesion, so-called active sites, were being preferentially occupied and filled. Since there was no evidence of drug agglomeration using scanning electron microscopy, the observations suggest that the number and range of such higher energy “active sites” can be reduced by modifying the surface roughness, that is, energies, of the carrier.
KW - Active sites
KW - Dry powder inhaler
KW - Lactose
KW - Smoothing
UR - http://www.scopus.com/inward/record.url?scp=33750847407&partnerID=8YFLogxK
U2 - 10.1080/03639040600712920
DO - 10.1080/03639040600712920
M3 - Article
C2 - 17090435
SN - 0363-9045
VL - 32
SP - 1135
EP - 1138
JO - Drug Development and Industrial Pharmacy
JF - Drug Development and Industrial Pharmacy
IS - 10
ER -